Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, Canham J, Thomas I, Johnson S, Gilkes A, Cavenagh J, Kottaridis P, Taussig D, Arnold C, Hemmaway C, Culligan D, Overgaard UM, Dennis M, Burnett AK, Russell NH, Dillon R. Othman J, et al. Among authors: mccarthy n. Blood. 2025 Oct 9;146(15):1862-1867. doi: 10.1182/blood.2025029556. Blood. 2025. PMID: 40768751 Clinical Trial.
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, Crawley C, Gilleece M, Peniket A, Protheroe R, Salim R, Tholouli E, Wilson K, Andrew G, Dillon R, Khan N, Potter V, Krishnamurthy P, Craddock C, Freeman S. Loke J, et al. Among authors: mccarthy n. Blood Adv. 2023 Jul 25;7(14):3666-3676. doi: 10.1182/bloodadvances.2022009493. Blood Adv. 2023. PMID: 37058448 Free PMC article.
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD. Russell NH, et al. Among authors: mccarthy n. J Clin Oncol. 2025 Feb 20;43(6):694-704. doi: 10.1200/JCO.24.00259. Epub 2024 Nov 18. J Clin Oncol. 2025. PMID: 39556780 Free PMC article. Clinical Trial.
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.
Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew GM, Dillon RJ, Gilkes AF, Marquez-Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne JL, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills RK, Freeman SD, Russell NH. Knapper S, et al. Among authors: mccarthy n. Blood. 2025 Nov 14:blood.2025031006. doi: 10.1182/blood.2025031006. Online ahead of print. Blood. 2025. PMID: 41237344
A replicating RNA vaccine protects cynomolgus macaques against lethal clade 2.3.4.4b influenza A H5N1 virus challenge.
Hawman DW, Griffin A, McCarthy N, Okumura A, Leventhal SS, Agumamidi M, Chorabik M Jr, Altynova E, Lewis M, Hinkley T, Stone ET, Warner N, Park S, Lovaglio J, Smith BJ, Hanley P, Saturday G, Shaia C, Clancy C, Rosenke K, Erasmus JH, Feldmann H. Hawman DW, et al. Among authors: mccarthy n. Sci Transl Med. 2025 Oct 8;17(819):eadw4646. doi: 10.1126/scitranslmed.adw4646. Epub 2025 Oct 8. Sci Transl Med. 2025. PMID: 41061043
Process Development of a Model Solvate for Drying Research.
McCarthy NH, Alsaiari NS, Brown T, Mahdi FM, Bayly AE, Finn S, Muller FL. McCarthy NH, et al. Org Process Res Dev. 2025 Aug 26;29(9):2200-2209. doi: 10.1021/acs.oprd.5c00095. eCollection 2025 Sep 19. Org Process Res Dev. 2025. PMID: 40994534 Free PMC article.
738 results